Cargando…

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

BACKGROUND: Tumour-infiltrating lymphocytes (TILs) have been demonstrated to significantly influence prognosis and response to therapy of invasive breast cancer (IBC). Thus, it has been suggested that TIL density or/and immunophenotype could serve as biomarkers for selection of IBC patients for immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beguinot, Marie, Dauplat, Marie-Melanie, Kwiatkowski, Fabrice, Lebouedec, Guillaume, Tixier, Lucie, Pomel, Christophe, Penault-Llorca, Frederique, Radosevic-Robin, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797400/ https://www.ncbi.nlm.nih.gov/pubmed/29394917 http://dx.doi.org/10.1186/s12885-018-4013-6

Ejemplares similares

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
por: Caparica, Rafael, et al.
Publicado: (2021)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Morphological and Immunohistochemical Study of Ovarian and Tubal Dysplasia Associated with Tamoxifen
por: Chene, G., et al.
Publicado: (2014)

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
por: Gay-Bellile, Mathilde, et al.
Publicado: (2017)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients
por: Lusho, Sejdi, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
por: Amat, S, et al.
Publicado: (2003)

ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis
por: Gay‐Bellile, Mathilde, et al.
Publicado: (2016)

BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells
por: Privat, Maud, et al.
Publicado: (2014)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2017)

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
por: Dufour, Robin, et al.
Publicado: (2015)

Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience
por: Cutuli, B, et al.
Publicado: (2009)

Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ
por: Xu, Fei-Fei, et al.
Publicado: (2021)

Is There a Relationship between Ovarian Epithelial Dysplasia and Infertility?
por: Chene, Gautier, et al.
Publicado: (2012)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

Fibroadenoma progress to ductal carcinoma in situ, infiltrating ductal carcinoma and lymph node metastasis? Report an unusual case
por: Wu, Yu-Ting, et al.
Publicado: (2017)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

More microinvasive foci in larger tumours of breast ductal carcinoma in situ
por: Chen, Xiao-Yang, et al.
Publicado: (2022)

Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials
por: Abrial, Catherine, et al.
Publicado: (2009)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast
por: Badve, Sunil S., et al.
Publicado: (2022)

Infiltrating ductal carcinoma breast with central necrosis closely mimicking ductal carcinoma in situ (comedo type): a case series
por: Pervez, Shahid, et al.
Publicado: (2007)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

Ductal carcinoma in situ (DCIS)
por: Holland, R
Publicado: (2002)

Ductal Carcinoma In Situ of the Breast
por: Lee, Richard J., et al.
Publicado: (2012)

Breast Ductal Carcinoma In Situ
por: Sacchini, Virgilio, et al.
Publicado: (2012)

Chemical biology fluorescent tools for in vitro investigation of the multidrug resistant P-glycoprotein (P-gp) expression in tumor cells
por: Daumar, Pierre, et al.
Publicado: (2023)

Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
por: Chollet, P, et al.
Publicado: (2003)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ
por: Zhou, Wenjing, et al.
Publicado: (2013)

CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
por: Morita, Michi, et al.
Publicado: (2016)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
por: Chollet, P, et al.
Publicado: (2002)

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
por: Wei, Zhang, et al.
Publicado: (2012)

La recherche de la surexpression de la protéine et l'amplification du gène HER2 dans le cancer de l'estomac par immunohistochimie et Hybridation in Situ: expérience du CHU HASSAN II de Fès
por: El Fatemi, Hinde, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5u27lr89h441c31f2fumac3k5u